All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Constantine Tam is Director of Haematology at the St Vincent’s Hospital, Melbourne, AU, as well as Disease Group Lead for chronic lymphocytic leukemia and low-grade lymphoma at the Victorian Comprehensive Cancer Centre, Melbourne, AU. He is an internationally recognized expert in targeted therapies for B-cell malignancies and leads multiple clinical trials for the novel BTK inhibitor, BGB-3111, as well as the first clinical trial in the world to combine ibrutinib and venetoclax.
Prof. Tam graduated MBBS (Hons) in 1998, completing his hematology training at the University of Melbourne, Melbourne, AU, and a Leukemia Fellowship at The University of Texas MD Anderson Cancer Center, Texas, US. He was awarded a research Doctor of Medicine in 2009 at the University of Melbourne.
Prof. Tam has authored 149 papers as well as numerous book chapters and receives research funding from the Victorian Cancer Agency, Australian Government National Health and Medical Research Council (NHRMC), Leukemia and Lymphoma Society, American Institute for Cancer Research (AICR), St Vincent’s Curran Endowment Fund, CLL Global Research Foundation, The Viertel Charitable Foundation, and the CASS Foundation. In 2013, Prof. Tam was awarded the Herman Clinical Fellowship for Translational Cancer Research by the University of Melbourne.
Positions of responsibility/awards: